• The glycosylation analysis services market is projected to reach nearly USD 2.5 billion by 2030

    The rapidly growing pipeline of recombinant glycoprotein therapeutics, especially the glycoengineered variants of COVID-19 drugs, has presented lucrative opportunities for contract service providers with expertise in glycoconjugate / glycan analysis

    For additional details, please visit
    https://www.rootsanalysis.com/reports/glycosylation-analysis-services-market.html
    The glycosylation analysis services market is projected to reach nearly USD 2.5 billion by 2030 The rapidly growing pipeline of recombinant glycoprotein therapeutics, especially the glycoengineered variants of COVID-19 drugs, has presented lucrative opportunities for contract service providers with expertise in glycoconjugate / glycan analysis For additional details, please visit https://www.rootsanalysis.com/reports/glycosylation-analysis-services-market.html
    Glycosylation Analysis Services Market 2021-2030 | Market Size | Industry Analysis | 2030
    Glycosylation Analysis Services Market report features an extensive study of the current market landscape and future potential of the...
    WWW.ROOTSANALYSIS.COM
    0 Comments 0 Shares
  • The glycosylation analysis services market is projected to reach nearly USD 2.5 billion by 2030

    The rapidly growing pipeline of recombinant glycoprotein therapeutics, especially the glycoengineered variants of COVID-19 drugs, has presented lucrative opportunities for contract service providers with expertise in glycoconjugate / glycan analysis

    For additional details, please visit
    https://www.rootsanalysis.com/reports/glycosylation-analysis-services-market.html
    The glycosylation analysis services market is projected to reach nearly USD 2.5 billion by 2030 The rapidly growing pipeline of recombinant glycoprotein therapeutics, especially the glycoengineered variants of COVID-19 drugs, has presented lucrative opportunities for contract service providers with expertise in glycoconjugate / glycan analysis For additional details, please visit https://www.rootsanalysis.com/reports/glycosylation-analysis-services-market.html
    Glycosylation Analysis Services Market 2021-2030 | Market Size | Industry Analysis | 2030
    Glycosylation Analysis Services Market report features an extensive study of the current market landscape and future potential of the...
    WWW.ROOTSANALYSIS.COM
    0 Comments 0 Shares
  • The global digital therapeutics market is projected to be worth over USD 8.86 billion by 2030

    Recent advances in information technology and biomedical science have enabled the development of a number of versatile digital solutions that are capable of either mimicking or augmenting, the fundamental qualities of pharmacological interventions

    For additional details, please visit
    https://www.rootsanalysis.com/reports/view_document/digital-health-market-focus-on-digital-therapeutic-monitoring-and-diag/208.html
    The global digital therapeutics market is projected to be worth over USD 8.86 billion by 2030 Recent advances in information technology and biomedical science have enabled the development of a number of versatile digital solutions that are capable of either mimicking or augmenting, the fundamental qualities of pharmacological interventions For additional details, please visit https://www.rootsanalysis.com/reports/view_document/digital-health-market-focus-on-digital-therapeutic-monitoring-and-diag/208.html
    0 Comments 0 Shares
  • The global digital therapeutics market is projected to be worth over USD 8.86 billion by 2030, growing at a CAGR of 19.7%

    Recent advances in information technology and biomedical science have enabled the development of a number of versatile digital solutions that are capable of either mimicking or augmenting, the fundamental qualities of pharmacological interventions

    For additional details, please visit
    https://www.rootsanalysis.com/reports/view_document/digital-health-market-focus-on-digital-therapeutic-monitoring-and-diag/208.html
    The global digital therapeutics market is projected to be worth over USD 8.86 billion by 2030, growing at a CAGR of 19.7% Recent advances in information technology and biomedical science have enabled the development of a number of versatile digital solutions that are capable of either mimicking or augmenting, the fundamental qualities of pharmacological interventions For additional details, please visit https://www.rootsanalysis.com/reports/view_document/digital-health-market-focus-on-digital-therapeutic-monitoring-and-diag/208.html
    0 Comments 0 Shares
  • Despite of an exhaustive mechanism of DNA processing and its highly stable structure, DNA is bound to undergo damage by several factors


    DNA damage can be referred to as any adverse alteration, which may occur in the form of base additions, base deletions or break in the sister DNA strands. Damage of genetic material is known to interfere with essential cellular processes, such as transcription and DNA replication.

    For additional details, please visit
    https://www.rootsanalysis.com/reports/dna-damage-response-targeting-therapeutics-market.html
    Despite of an exhaustive mechanism of DNA processing and its highly stable structure, DNA is bound to undergo damage by several factors DNA damage can be referred to as any adverse alteration, which may occur in the form of base additions, base deletions or break in the sister DNA strands. Damage of genetic material is known to interfere with essential cellular processes, such as transcription and DNA replication. For additional details, please visit https://www.rootsanalysis.com/reports/dna-damage-response-targeting-therapeutics-market.html
    DNA Damage Response Market | DDR Therapeutics | DDR Drugs Market | DNA Damage Response Drugs Market | Market Size | 2030
    With promising development pipeline and encouraging clinical trial results, DDR targeting therapeutics market is anticipated to reach over USD 1 billion by 2030
    WWW.ROOTSANALYSIS.COM
    0 Comments 0 Shares
  • The global digital therapeutics market is projected to be worth over USD 8.86 billion by 2030

    Recent advances in information technology and biomedical science have enabled the development of a number of versatile digital solutions that are capable of either mimicking or augmenting, the fundamental qualities of pharmacological interventions

    For additional details, please visit
    https://www.rootsanalysis.com/reports/view_document/digital-health-market-focus-on-digital-therapeutic-monitoring-and-diag/208.html
    The global digital therapeutics market is projected to be worth over USD 8.86 billion by 2030 Recent advances in information technology and biomedical science have enabled the development of a number of versatile digital solutions that are capable of either mimicking or augmenting, the fundamental qualities of pharmacological interventions For additional details, please visit https://www.rootsanalysis.com/reports/view_document/digital-health-market-focus-on-digital-therapeutic-monitoring-and-diag/208.html
    0 Comments 0 Shares
  • The blood-brain barrier (BBB) penetrating drugs market is estimated to be worth USD 900 million

    Advances in biotechnology have enabled the development of versatile in vitro (static and dynamic), in vivo (micro-dialysis), and in situ (brain perfusion) blood–brain barrier models, allowing more effective and safe delivery of drugs across brain capillaries

    Over time, extensive R&D efforts have resulted in the development of a number of versatile BBB penetration technologies. These technologies have been designed either to externally alter the permeability of the blood csf barrier or augment the BBB penetrating capabilities of compatible pharmacological interventions.

    Roots Analysis is pleased to announce the publication of its recent study, titled, “Blood-Brain Barrier (BBB) Market (2nd Edition), 2020-2030: Focus on Non-Invasive Drug Delivery Technology Platforms and Therapeutics.”

    To request a sample copy / brochure of this report, please visit
    https://www.rootsanalysis.com/reports/310/request-sample.html

    The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of BBB penetration technologies and affiliated drugs, over the next decade. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. In addition to other elements, the study includes:
     More than 110 drugs, capable of penetrating this elusive barrier are currently being evaluated for the treatment of CNS drugs disorders; there are 35+ technology platforms for the development of BBB penetrant drugs
     An overview of the overall landscape of BBB penetration technologies, featuring an in-depth analysis of the technologies based on a number of parameters
     A detailed assessment of the current market landscape of BBB penetrant drugs.
     Identification of contemporary market trends depicted using three schematic representations, which include [A] a tree map representation, [B] a bubble analysis and [C] an informative heptagon representation.
     An insightful competitiveness analysis of BBB penetration technologies, taking into consideration the supplier power and key technology specific information.
     Elaborate profiles of prominent technology developers that are engaged in the development of at least four drugs.
     An analysis of the partnerships that have been established in the domain, in the period between 2014 and 2020.
     An elaborate discussion on the deal structures of various types of technology licensing agreements inked in this domain.
     An analysis of the investments made in the domain, in the period between 2014 and 2020 (till March).
     An in-depth analysis of the various patents that have been filed / granted related to BBB penetration technologies, till November 2019.
     An insightful chessboard analysis highlighting the most preferred / popular drug development strategies / paths adopted by majority of the drug developers (with clinical candidates) in order to progress their lead drug candidates.
     An assessment of the most commonly targeted disorders affecting the central nervous system , shortlisted on the basis of number of BBB penetrant drugs in development.
     A list of 240+ drug developers targeting Alzheimer’s disease and Parkinson’s disease that are likely to partner with BBB penetration technology providers.
     A case study highlighting the working principle of the most common approaches that are being employed for the development of BBB penetration technologies.
     An informative analysis of contemporary Google Trends in the time period between 2015 and 2019 (till December) and insights generated from recent news articles related to the BBB, indicating the increasing popularity of this domain.
    A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below) :
     Type of Payment Model Adopted
     Upfront payments
     Milestone payments

     Type of Molecule
     Small Molecules
     Biologics

     Target Disease Indication
     Brain Metastases in Breast Cancer
     Glioblastoma Multiforme
     Hunter Syndrome
     Hurler Syndrome

     Leading Technology Platforms
     G®-Technology
     J-Brain Cargo® Technology
     LRP-1 Technology
     Trojan Horse Technology

     Leading Drug Developers
     2-BBB
     Angiochem
     ArmaGen
     JCR Pharmaceuticals

     Key Geographical Regions
     North America
     Europe
     Asia-Pacific

    Transcripts of interviews held with the following senior level representatives of stakeholder companies
     Ram Bhatt (Chief Executive Officer, Chairman and Founder, Innovative California Biosciences International (ICBI))
     Frank S Walsh (Chief Executive Officer and Founder, Ossianix)
     Pieter Gaillard (Chief Executive Officer and Co-Founder, 2-BBB)
     Rob Hutchison (Chief Executive Officer and Chairman, biOasis Technologies)
     Mathias Schmidt (Chief Executive Officer, ArmaGen)
     Mark L Peterson (Chief Operating Officer, Cyclenium Pharma)
     Xavier Rivero (Chief Operating Officer, Sagetis Biotech)
     Carole Desseaux (Head of Clinical Affairs, CarThera)
     Jamal Temsamani (Head of Drug Development, Vect-Horus)
     Kevin Kit Parker (Professor, Wyss Institute, Harvard University)

    Key companies covered in the report
     Angiochem
     ArmaGen
     BioArctic
     Cyclenium Pharma
     Denali Therapeutics
     ICB International
     Iproteos
     JCR Pharmaceuticals
     Lauren Sciences
     Medesis Pharma
     Ossianix
     Vect-Horus

    For additional details, please visit
    https://www.rootsanalysis.com/reports/view_document/blood-brain-barrier-drug-delivery/310.html or email sales@rootsanalysis.com

    You may also be interested in the following titles:
    1. Novel Coronavirus (Covid-19): Preventive Vaccines, Therapeutics and Diagnostics in Development
    2. DNA-Encoded Libraries: Platforms and Services Market
    3. Global Stem Cells Market: Focus on Clinical Therapies, 2020–2030


    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com


    Contact:
    Ben Johnson
    +1 (415) 800 3415
    +44 (122) 391 1091
    Ben.johnson@rootsanalysis.com

    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis
    Medium - https://medium.com/@RootsAnalysis
    Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora - https://rootsanalysisinsights.quora.com/
    The blood-brain barrier (BBB) penetrating drugs market is estimated to be worth USD 900 million Advances in biotechnology have enabled the development of versatile in vitro (static and dynamic), in vivo (micro-dialysis), and in situ (brain perfusion) blood–brain barrier models, allowing more effective and safe delivery of drugs across brain capillaries Over time, extensive R&D efforts have resulted in the development of a number of versatile BBB penetration technologies. These technologies have been designed either to externally alter the permeability of the blood csf barrier or augment the BBB penetrating capabilities of compatible pharmacological interventions. Roots Analysis is pleased to announce the publication of its recent study, titled, “Blood-Brain Barrier (BBB) Market (2nd Edition), 2020-2030: Focus on Non-Invasive Drug Delivery Technology Platforms and Therapeutics.” To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/310/request-sample.html The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of BBB penetration technologies and affiliated drugs, over the next decade. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. In addition to other elements, the study includes:  More than 110 drugs, capable of penetrating this elusive barrier are currently being evaluated for the treatment of CNS drugs disorders; there are 35+ technology platforms for the development of BBB penetrant drugs  An overview of the overall landscape of BBB penetration technologies, featuring an in-depth analysis of the technologies based on a number of parameters  A detailed assessment of the current market landscape of BBB penetrant drugs.  Identification of contemporary market trends depicted using three schematic representations, which include [A] a tree map representation, [B] a bubble analysis and [C] an informative heptagon representation.  An insightful competitiveness analysis of BBB penetration technologies, taking into consideration the supplier power and key technology specific information.  Elaborate profiles of prominent technology developers that are engaged in the development of at least four drugs.  An analysis of the partnerships that have been established in the domain, in the period between 2014 and 2020.  An elaborate discussion on the deal structures of various types of technology licensing agreements inked in this domain.  An analysis of the investments made in the domain, in the period between 2014 and 2020 (till March).  An in-depth analysis of the various patents that have been filed / granted related to BBB penetration technologies, till November 2019.  An insightful chessboard analysis highlighting the most preferred / popular drug development strategies / paths adopted by majority of the drug developers (with clinical candidates) in order to progress their lead drug candidates.  An assessment of the most commonly targeted disorders affecting the central nervous system , shortlisted on the basis of number of BBB penetrant drugs in development.  A list of 240+ drug developers targeting Alzheimer’s disease and Parkinson’s disease that are likely to partner with BBB penetration technology providers.  A case study highlighting the working principle of the most common approaches that are being employed for the development of BBB penetration technologies.  An informative analysis of contemporary Google Trends in the time period between 2015 and 2019 (till December) and insights generated from recent news articles related to the BBB, indicating the increasing popularity of this domain. A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below) :  Type of Payment Model Adopted  Upfront payments  Milestone payments  Type of Molecule  Small Molecules  Biologics  Target Disease Indication  Brain Metastases in Breast Cancer  Glioblastoma Multiforme  Hunter Syndrome  Hurler Syndrome  Leading Technology Platforms  G®-Technology  J-Brain Cargo® Technology  LRP-1 Technology  Trojan Horse Technology  Leading Drug Developers  2-BBB  Angiochem  ArmaGen  JCR Pharmaceuticals  Key Geographical Regions  North America  Europe  Asia-Pacific Transcripts of interviews held with the following senior level representatives of stakeholder companies  Ram Bhatt (Chief Executive Officer, Chairman and Founder, Innovative California Biosciences International (ICBI))  Frank S Walsh (Chief Executive Officer and Founder, Ossianix)  Pieter Gaillard (Chief Executive Officer and Co-Founder, 2-BBB)  Rob Hutchison (Chief Executive Officer and Chairman, biOasis Technologies)  Mathias Schmidt (Chief Executive Officer, ArmaGen)  Mark L Peterson (Chief Operating Officer, Cyclenium Pharma)  Xavier Rivero (Chief Operating Officer, Sagetis Biotech)  Carole Desseaux (Head of Clinical Affairs, CarThera)  Jamal Temsamani (Head of Drug Development, Vect-Horus)  Kevin Kit Parker (Professor, Wyss Institute, Harvard University) Key companies covered in the report  Angiochem  ArmaGen  BioArctic  Cyclenium Pharma  Denali Therapeutics  ICB International  Iproteos  JCR Pharmaceuticals  Lauren Sciences  Medesis Pharma  Ossianix  Vect-Horus For additional details, please visit https://www.rootsanalysis.com/reports/view_document/blood-brain-barrier-drug-delivery/310.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Novel Coronavirus (Covid-19): Preventive Vaccines, Therapeutics and Diagnostics in Development 2. DNA-Encoded Libraries: Platforms and Services Market 3. Global Stem Cells Market: Focus on Clinical Therapies, 2020–2030 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
    Request Sample - Blood-Brain Barrier (BBB) | Industry Analysis | Market Size | 2030
    Blood-Brain Barrier (BBB) Market, 2020-2030: Focus on Non-Invasive Drug Delivery Technology Platforms and Therapeutics Nanoparticle based Approaches)
    WWW.ROOTSANALYSIS.COM
    0 Comments 0 Shares
  • The soft tissue sarcoma market is projected to be worth over USD 420 million in 2030

    Recent advances in molecular biology have enabled researchers to develop a better understanding of the rare soft tissue sarcomas; as a result, a number of viable biological targets have been identified and are being investigated for therapeutic relevance

    Roots Analysis has announced the addition of “Soft Tissue Sarcoma: Focus on Angiosarcoma, Chondrosarcoma, and Liposarcoma Market, 2021-2030” report to its list of offerings.

    Soft tissue sarcoma is a rare form of cancer that usually originates in soft / connective tissues and most commonly affects the abdomen, arms, head, legs, neck and trunk of the individual. It is worth noting that, till date, many types (50+) of soft tissue sarcoma have been identified. However, since these tumors possess a large set of entities, their diagnosis is often difficult. At present, there is a growing need for effective and targeted treatment options.

    To order this 130+ slides report, which features 80+ figures, please visit https://www.rootsanalysis.com/reports/soft-tissue-sarcoma-market.html.

    Key Market Insights

    70+ therapeutics have been / are being developed for the treatment of angiosarcoma, chondrosarcoma and liposarcoma
    Nearly 95% of the aforementioned therapeutic candidates are under clinical evaluation. Further, two therapies, namely YONDELIS® and HALAVEN®, have been approved for the treatment of liposarcoma.

    Around 65% of the therapeutics are being developed as small molecules
    Majority (over 65%) of the abovementioned drugs have been / are being developed for administration via the oral route. Notably, about 60% of the soft tissue sarcoma targeting therapeutics have been / are being developed for use as the 1st line of treatment.

    More than 50 industry and non-industry players are engaged in the soft tissue sarcoma market
    North America has emerged as a key hub, featuring the presence of close to 60% developers. The developer landscape is further dominated by players that have been established after 1990, representing around 45% of the total number of stakeholders.

    Around 190 trials, evaluating therapies for soft tissue sarcoma, have been registered
    More than 22,000 patients have been enrolled in clinical research initiatives aimed to validate the efficacy and safety of soft tissue sarcoma targeting therapeutics. Interestingly, 60% of the overall trials are phase II studies; of these, 50% are currently active.

    Partnership activity in this field has increased at a CAGR of 70%, between 2018 and 2020
    About 80% of the reported deals were established in the last three years, with the maximum activity being reported in 2020. Majority of the instances captured in the report were licensing agreements (45%). Further, more than 50% of the agreements were observed to be signed for therapeutics targeting liposarcoma.

    More than 260 articles have been published related to soft tissue sarcoma, since January 2021
    Around 40% publications mentioned in the report were focused on the assessment of therapeutics that have been / are being developed for the treatment of angiosarcoma. Example of prominent journals include (in decreasing order of number of publications) BMJ Case Rep, Skeletal Radiol, Ann Surg Oncol and Cureus.

    Around 75 eminent scientists were identified as key opinion leaders (KOLs)
    65% of these KOLs were observed to be associated with organizations based in North America, followed by those affiliated to institutes in Europe (30%) and Asia-Pacific (5%). Further, majority (50%) of the KOLs are currently affiliated to academic institutes, such as schools and universities.

    North America is anticipated to capture over 70% of the global market share in 2030
    In 2030, nearly 80% of the market revenues are expected to be generated from sales of therapeutics that intended for the treatment of liposarcoma. Further, therapies designed for intravenous administration are expected to occupy a larger share (60%) of the overall market in 2030.

    To request a sample copy / brochure of this report, please visit this
    https://www.rootsanalysis.com/reports/soft-tissue-sarcoma-market/request-sample.html

    Key Questions Answered
     Who are the leading players engaged in the development of soft tissue sarcoma targeting therapeutics?
     Which is the most popular type of soft tissue sarcoma, based on the ongoing activity in the market?
     Which are the most common routes of administration for soft tissue sarcoma targeting therapeutics?
     Which companies are actively involved in conducting clinical trials for their therapeutic candidates?
     Which partnership models are most commonly adopted by stakeholders in this industry?
     What is the evolving trend related to the focus of publications related to soft tissue sarcoma targeting therapeutics?
     Who are the prominent KOLs evaluating therapies within this industry?
     What opportunities are available for soft tissue sarcoma targeting therapeutics in emerging markets?
     How is the current and future opportunity likely to be distributed across key market segments?


    The USD 421 million (by 2030) financial opportunity within the soft tissue sarcoma targeting therapeutics market has been analyzed across the following segments:

     Drug Class
     Biologics
     Small Molecules

     Route of Administration
     Intravenous Drugs
     Oral Drugs

     Type of Soft Tissue Sarcoma
     Angiosarcoma
     Chondrosarcoma
     Liposarcoma

     Key Geographical Regions
     North America
     Europe
     Asia-Pacific
     Rest of the World

    The research includes profiles of key players (listed below); each profile features a brief overview of company, pipeline details, recent developments (including collaborations and expansions) and an informed future outlook.

     Adaptimmune
     Agios Pharmaceuticals
     Agenus
     Athenex
     Eisai
     Eli Lilly
     GlaxoSmithKline
     Karyopharm Therapeutics
     Mirati Therapeutics
     PharmaMar

    For additional details, please visit https://www.rootsanalysis.com/reports/soft-tissue-sarcoma-market.html or email sales@rootsanalysis.com

    You may also be interested in the following titles:
    1. Progressive Supranuclear Palsy: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030
    2. Squamous Non-Small Cell Lung Cancer: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030
    3. Polycystic Ovarian Syndrome (PCOS): Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030

    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

    Contact Information
    Roots Analysis Private Limited
    Ben Johnson
    +1 (415) 800 3415
    ben.johnson@rootsanalysis.com
    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis
    Medium - https://medium.com/@RootsAnalysis
    Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora - https://rootsanalysisinsights.quora.com/
    The soft tissue sarcoma market is projected to be worth over USD 420 million in 2030 Recent advances in molecular biology have enabled researchers to develop a better understanding of the rare soft tissue sarcomas; as a result, a number of viable biological targets have been identified and are being investigated for therapeutic relevance Roots Analysis has announced the addition of “Soft Tissue Sarcoma: Focus on Angiosarcoma, Chondrosarcoma, and Liposarcoma Market, 2021-2030” report to its list of offerings. Soft tissue sarcoma is a rare form of cancer that usually originates in soft / connective tissues and most commonly affects the abdomen, arms, head, legs, neck and trunk of the individual. It is worth noting that, till date, many types (50+) of soft tissue sarcoma have been identified. However, since these tumors possess a large set of entities, their diagnosis is often difficult. At present, there is a growing need for effective and targeted treatment options. To order this 130+ slides report, which features 80+ figures, please visit https://www.rootsanalysis.com/reports/soft-tissue-sarcoma-market.html. Key Market Insights 70+ therapeutics have been / are being developed for the treatment of angiosarcoma, chondrosarcoma and liposarcoma Nearly 95% of the aforementioned therapeutic candidates are under clinical evaluation. Further, two therapies, namely YONDELIS® and HALAVEN®, have been approved for the treatment of liposarcoma. Around 65% of the therapeutics are being developed as small molecules Majority (over 65%) of the abovementioned drugs have been / are being developed for administration via the oral route. Notably, about 60% of the soft tissue sarcoma targeting therapeutics have been / are being developed for use as the 1st line of treatment. More than 50 industry and non-industry players are engaged in the soft tissue sarcoma market North America has emerged as a key hub, featuring the presence of close to 60% developers. The developer landscape is further dominated by players that have been established after 1990, representing around 45% of the total number of stakeholders. Around 190 trials, evaluating therapies for soft tissue sarcoma, have been registered More than 22,000 patients have been enrolled in clinical research initiatives aimed to validate the efficacy and safety of soft tissue sarcoma targeting therapeutics. Interestingly, 60% of the overall trials are phase II studies; of these, 50% are currently active. Partnership activity in this field has increased at a CAGR of 70%, between 2018 and 2020 About 80% of the reported deals were established in the last three years, with the maximum activity being reported in 2020. Majority of the instances captured in the report were licensing agreements (45%). Further, more than 50% of the agreements were observed to be signed for therapeutics targeting liposarcoma. More than 260 articles have been published related to soft tissue sarcoma, since January 2021 Around 40% publications mentioned in the report were focused on the assessment of therapeutics that have been / are being developed for the treatment of angiosarcoma. Example of prominent journals include (in decreasing order of number of publications) BMJ Case Rep, Skeletal Radiol, Ann Surg Oncol and Cureus. Around 75 eminent scientists were identified as key opinion leaders (KOLs) 65% of these KOLs were observed to be associated with organizations based in North America, followed by those affiliated to institutes in Europe (30%) and Asia-Pacific (5%). Further, majority (50%) of the KOLs are currently affiliated to academic institutes, such as schools and universities. North America is anticipated to capture over 70% of the global market share in 2030 In 2030, nearly 80% of the market revenues are expected to be generated from sales of therapeutics that intended for the treatment of liposarcoma. Further, therapies designed for intravenous administration are expected to occupy a larger share (60%) of the overall market in 2030. To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/soft-tissue-sarcoma-market/request-sample.html Key Questions Answered  Who are the leading players engaged in the development of soft tissue sarcoma targeting therapeutics?  Which is the most popular type of soft tissue sarcoma, based on the ongoing activity in the market?  Which are the most common routes of administration for soft tissue sarcoma targeting therapeutics?  Which companies are actively involved in conducting clinical trials for their therapeutic candidates?  Which partnership models are most commonly adopted by stakeholders in this industry?  What is the evolving trend related to the focus of publications related to soft tissue sarcoma targeting therapeutics?  Who are the prominent KOLs evaluating therapies within this industry?  What opportunities are available for soft tissue sarcoma targeting therapeutics in emerging markets?  How is the current and future opportunity likely to be distributed across key market segments? The USD 421 million (by 2030) financial opportunity within the soft tissue sarcoma targeting therapeutics market has been analyzed across the following segments:  Drug Class  Biologics  Small Molecules  Route of Administration  Intravenous Drugs  Oral Drugs  Type of Soft Tissue Sarcoma  Angiosarcoma  Chondrosarcoma  Liposarcoma  Key Geographical Regions  North America  Europe  Asia-Pacific  Rest of the World The research includes profiles of key players (listed below); each profile features a brief overview of company, pipeline details, recent developments (including collaborations and expansions) and an informed future outlook.  Adaptimmune  Agios Pharmaceuticals  Agenus  Athenex  Eisai  Eli Lilly  GlaxoSmithKline  Karyopharm Therapeutics  Mirati Therapeutics  PharmaMar For additional details, please visit https://www.rootsanalysis.com/reports/soft-tissue-sarcoma-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Progressive Supranuclear Palsy: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030 2. Squamous Non-Small Cell Lung Cancer: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030 3. Polycystic Ovarian Syndrome (PCOS): Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Ben Johnson +1 (415) 800 3415 ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
    0 Comments 0 Shares
  • The bispecific antibody therapeutics market is estimated to be worth USD 6.9 billion in 2030

    Bispecific antibody therapeutics represent a transformative approach to modern treatment; over the years, this upcoming class of ‘two-target’ artificially engineered drugs have generated significant enthusiasm within the medical science community

    For more information please click on the following link:
    https://www.rootsanalysis.com/reports/view_document/bispecific-antibodies/286.html
    The bispecific antibody therapeutics market is estimated to be worth USD 6.9 billion in 2030 Bispecific antibody therapeutics represent a transformative approach to modern treatment; over the years, this upcoming class of ‘two-target’ artificially engineered drugs have generated significant enthusiasm within the medical science community For more information please click on the following link: https://www.rootsanalysis.com/reports/view_document/bispecific-antibodies/286.html
    Bispecific Antibody Therapeutics Market (4th Edition) | Market Size | Industry Analysis | 2030
    Market research report on bispecific antibody therapeutics; the study includes details on current market landscape and future growth opportunities
    WWW.ROOTSANALYSIS.COM
    0 Comments 0 Shares
  • The CAR-T therapies market is characterized by a healthy pipeline of promising therapies

    Given the success of approved CAR-T cell therapies, such as KYMRIAH®, YESCARTA®, TECARTUS® and BREYANZI®, this upcoming class of biologics are anticipated to carve out a significant share of the multi-billion dollar cancer immunotherapy market

    Roots Analysis has announced the addition of “CAR-T Cell Therapy Market (3rd Edition) by Target Indications (NHL, Multiple Myeloma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma, Hepatocellular Carcinoma and Others), Target Antigens (CD19, BCMA, CD19 / CD22, GPC3 and EGFR), Key Players and Key Geographies (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World) – Industry Trends and Global Forecasts, 2021-2030” report to its list of offerings.

    Given their ability to selectively direct a cell mediated immune response against cancer cells and, thereby, offer prolonged periods of disease remission, several CAR-T cell therapies provide a promising therapeutic strategy for advanced stage cancers and are expected to achieve blockbuster status. With four approved products and many candidate therapies under evaluation for the treatment of multiple disease indications, the CAR-T cell therapy market is characterized by a healthy and growing pipeline. Further, with lucrative financial support and notable increase in partnerships, the CAR-T-cell therapies market is abuzz with activity.

    To order this 795+ page report, which features 165+ figures and 270+ tables, please visit https://www.rootsanalysis.com/reports/view_document/car-t-therapies-market/269.html

    Key Market Insights

    Over 755 CAR-T cell therapies are currently approved / under development
    Close to 40% of the aforementioned candidates are in preclinical and discovery stages, while more than 25% are being evaluated in clinical stages (phase I/II and above). Examples of late-stage clinical candidates include bb2121, CD123/CLL1 CAR-T CD19 CAR-T and LCAR-B38M CAR-T / JNJ-68284528.

    Currently, the focus is on developing product candidates to treat various types of cancers
    Over 95% of the products in the development pipeline are being evaluated for the treatment of hematological malignancies, including (in decreasing order of number of pipeline products) acute lymphoblastic leukemia, non-Hodgkin's lymphoma, multiple myeloma, and acute myeloid leukemia. Only 2% of current pipeline candidates are being developed for the treatment of non-oncological indications.

    Extensive efforts are underway to improve CAR constructs
    Majority of the product candidates in the clinical pipeline, including the four approved drug products, are based on second generation CARs. Further, a number of novel therapies armed with fourth generation CAR constructs, CAR-based products containing humanized scFv and bispecific CARs (CD19+CD20 or CD19+CD22 or CD19+CD30) are being evaluated worldwide.

    China is leading the product development efforts related to CAR-T cell therapies, in terms of number of active trials and supporting hospitals
    In the last 10 years, over half of the 410 clinical trials evaluating various types of CAR-T cell therapies, were registered in China. In addition, owning to a favorable clinical research environment, China is presently considered to be among the leading regions in the CAR-T cell therapy space, with close to 40 industry players and more than 100 non-industry players, including hospitals and universities, contributing to this field.

    Partnership activity within this domain has grown at a CAGR of 26%, between 2011 and 2020
    More than 220 agreements were inked related to CAR-T cell therapies, with the maximum activity being reported in 2018. Majority of partnership deals signed within this domain were R&D agreements (21%), technology licensing (20%) and product development and commercialization agreements (11%).

    Over USD 13 billion has been invested by both private and public investors, across more than 205 instances
    It is important to mention that, between 2013 and 2020, majority of the funding was acquired through venture capital rounds (37%), other equity financing elements (24%), grants (12%) and secondary offerings (12%).

    The market is anticipated to grow at a CAGR of over 28%, during the period 2021-2030
    Growth in this domain is anticipated to be primarily driven by encouraging clinical trial results and the recent success of the four approved CAR-T cell therapies. North America (primarily the US) and Europe are expected to capture over 75% of the market share by 2030, in terms of the sales-based revenues.

    To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/269/request-sample.html

    Key Questions Answered
     Who are the leading industry and non-industry players in this market?
     What are the prevalent R&D trends in CAR-T cell therapies domain?
     What are the key therapeutic areas for which CAR-T cell therapies are being / have been developed?
     What are the challenges faced by stakeholders in this industry?
     Which are the key geographies where extensive research on CAR-T cell therapies is being conducted?
     Who are the key investors in this domain?
     Who are the key opinion leaders / experts that can help in driving product development efforts in this field?
     What kind of partnership models are commonly adopted by industry stakeholders?
     What kind of contract manufacturing support is available for CAR-T cell therapies?
     What kind of promotional strategies are likely to be adopted for CAR-T cell therapies that are approved / commercialized in future?
     What are the factors that are likely to influence the evolution of this upcoming market?
     How is the current and future market opportunity likely to be distributed across key market segments?


    The USD 14 billion (by 2030) financial opportunity within the CAR-T cell therapy market has been analyzed across the following segments:

     Disease indication
     Non-Hodgkin lymphoma
     Multiple myeloma
     Chronic lymphocytic leukemia
     Acute lymphoblastic leukemia
     Follicular lymphoma
     Mantle cell lymphoma
     Hepatocellular carcinoma
     Colorectal cancer

     Target antigens
     CD19
     BCMA
     CD19, CD22
     GPC3
     EGFR

     Key Geographical Regions
     North America
     Europe
     Asia Pacific
     Latin America
     Middle East and North Africa
     Rest of the World

    The report features inputs from eminent industry stakeholders, according to whom CAR-T cell therapies are soon likely to witness increased adoption given their broad scope of applications in various advanced stage oncological disorders. The report includes detailed transcripts of discussions held with the following experts:
     Tim Oldham (Chief Executive Officer, Cell Therapies)
     Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics)
     Wei (William) Cao (Co-Founder, Chairman and Chief Executive Officer, Gracell Biotechnologies)
     Miguel Forte (Chief Operating Officer, TxCell)
     Adrian Bot (Vice President, Scientific Affairs, Kite Pharma)
     Vincent Brichard (Vice President, Immuno-Oncology, Celyad)
     Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)
     Aino Kalervo (Competitive Intelligence Manager, Strategy & Business Development, Theravectys)
     Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital)
     Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado)

    The research includes brief profiles, featuring an overview of the company, its financial information (if available), and a description of its product(s), highlighting type of therapy and current development status. Each company profile includes technology portfolio (if available), recent developments related to T-cell immunotherapies and manufacturing capabilities of the companies.
     Autolus
     bluebird bio
     CARsgen Therapeutics
     Celgene (A Bristol Myers Squibb Company)
     Cellectis
     Cellular Biomedicine Group
     Innovative Cellular Therapeutics
     Iovance Biotherapeutics
     Kite Pharma (A Gilead Sciences Company)
     Kuur Therapeutics
     Noile-Immune Biotech
     Novartis
     Shanghai Genechem
     Sinobioway Cell Therapy
     Takara Bio
     Ziopharm Oncology

    For additional details, please visit
    https://www.rootsanalysis.com/reports/view_document/car-t-therapies-market/269.html or email sales@rootsanalysis.com

    You may also be interested in the following titles:
    1. Global T-Cell Therapies Market (5th Edition), 2021 – 2030
    2. mRNA Therapeutics and Vaccines Market, 2020-2030
    3. Gene Therapies Market (4th Edition): Industry Trends and Global Forecasts, 2020-2030
    4. Oncolytic Virus Therapy Market: Pipeline Review, Developer Landscape and Competitive Insights, 2020-2030


    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com


    Contact:
    Ben Johnson
    +1 (415) 800 3415
    +44 (122) 391 1091
    Ben.johnson@rootsanalysis.com

    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis
    Medium - https://medium.com/@RootsAnalysis
    Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora - https://rootsanalysisinsights.quora.com/
    The CAR-T therapies market is characterized by a healthy pipeline of promising therapies Given the success of approved CAR-T cell therapies, such as KYMRIAH®, YESCARTA®, TECARTUS® and BREYANZI®, this upcoming class of biologics are anticipated to carve out a significant share of the multi-billion dollar cancer immunotherapy market Roots Analysis has announced the addition of “CAR-T Cell Therapy Market (3rd Edition) by Target Indications (NHL, Multiple Myeloma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma, Hepatocellular Carcinoma and Others), Target Antigens (CD19, BCMA, CD19 / CD22, GPC3 and EGFR), Key Players and Key Geographies (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World) – Industry Trends and Global Forecasts, 2021-2030” report to its list of offerings. Given their ability to selectively direct a cell mediated immune response against cancer cells and, thereby, offer prolonged periods of disease remission, several CAR-T cell therapies provide a promising therapeutic strategy for advanced stage cancers and are expected to achieve blockbuster status. With four approved products and many candidate therapies under evaluation for the treatment of multiple disease indications, the CAR-T cell therapy market is characterized by a healthy and growing pipeline. Further, with lucrative financial support and notable increase in partnerships, the CAR-T-cell therapies market is abuzz with activity. To order this 795+ page report, which features 165+ figures and 270+ tables, please visit https://www.rootsanalysis.com/reports/view_document/car-t-therapies-market/269.html Key Market Insights Over 755 CAR-T cell therapies are currently approved / under development Close to 40% of the aforementioned candidates are in preclinical and discovery stages, while more than 25% are being evaluated in clinical stages (phase I/II and above). Examples of late-stage clinical candidates include bb2121, CD123/CLL1 CAR-T CD19 CAR-T and LCAR-B38M CAR-T / JNJ-68284528. Currently, the focus is on developing product candidates to treat various types of cancers Over 95% of the products in the development pipeline are being evaluated for the treatment of hematological malignancies, including (in decreasing order of number of pipeline products) acute lymphoblastic leukemia, non-Hodgkin's lymphoma, multiple myeloma, and acute myeloid leukemia. Only 2% of current pipeline candidates are being developed for the treatment of non-oncological indications. Extensive efforts are underway to improve CAR constructs Majority of the product candidates in the clinical pipeline, including the four approved drug products, are based on second generation CARs. Further, a number of novel therapies armed with fourth generation CAR constructs, CAR-based products containing humanized scFv and bispecific CARs (CD19+CD20 or CD19+CD22 or CD19+CD30) are being evaluated worldwide. China is leading the product development efforts related to CAR-T cell therapies, in terms of number of active trials and supporting hospitals In the last 10 years, over half of the 410 clinical trials evaluating various types of CAR-T cell therapies, were registered in China. In addition, owning to a favorable clinical research environment, China is presently considered to be among the leading regions in the CAR-T cell therapy space, with close to 40 industry players and more than 100 non-industry players, including hospitals and universities, contributing to this field. Partnership activity within this domain has grown at a CAGR of 26%, between 2011 and 2020 More than 220 agreements were inked related to CAR-T cell therapies, with the maximum activity being reported in 2018. Majority of partnership deals signed within this domain were R&D agreements (21%), technology licensing (20%) and product development and commercialization agreements (11%). Over USD 13 billion has been invested by both private and public investors, across more than 205 instances It is important to mention that, between 2013 and 2020, majority of the funding was acquired through venture capital rounds (37%), other equity financing elements (24%), grants (12%) and secondary offerings (12%). The market is anticipated to grow at a CAGR of over 28%, during the period 2021-2030 Growth in this domain is anticipated to be primarily driven by encouraging clinical trial results and the recent success of the four approved CAR-T cell therapies. North America (primarily the US) and Europe are expected to capture over 75% of the market share by 2030, in terms of the sales-based revenues. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/269/request-sample.html Key Questions Answered  Who are the leading industry and non-industry players in this market?  What are the prevalent R&D trends in CAR-T cell therapies domain?  What are the key therapeutic areas for which CAR-T cell therapies are being / have been developed?  What are the challenges faced by stakeholders in this industry?  Which are the key geographies where extensive research on CAR-T cell therapies is being conducted?  Who are the key investors in this domain?  Who are the key opinion leaders / experts that can help in driving product development efforts in this field?  What kind of partnership models are commonly adopted by industry stakeholders?  What kind of contract manufacturing support is available for CAR-T cell therapies?  What kind of promotional strategies are likely to be adopted for CAR-T cell therapies that are approved / commercialized in future?  What are the factors that are likely to influence the evolution of this upcoming market?  How is the current and future market opportunity likely to be distributed across key market segments? The USD 14 billion (by 2030) financial opportunity within the CAR-T cell therapy market has been analyzed across the following segments:  Disease indication  Non-Hodgkin lymphoma  Multiple myeloma  Chronic lymphocytic leukemia  Acute lymphoblastic leukemia  Follicular lymphoma  Mantle cell lymphoma  Hepatocellular carcinoma  Colorectal cancer  Target antigens  CD19  BCMA  CD19, CD22  GPC3  EGFR  Key Geographical Regions  North America  Europe  Asia Pacific  Latin America  Middle East and North Africa  Rest of the World The report features inputs from eminent industry stakeholders, according to whom CAR-T cell therapies are soon likely to witness increased adoption given their broad scope of applications in various advanced stage oncological disorders. The report includes detailed transcripts of discussions held with the following experts:  Tim Oldham (Chief Executive Officer, Cell Therapies)  Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics)  Wei (William) Cao (Co-Founder, Chairman and Chief Executive Officer, Gracell Biotechnologies)  Miguel Forte (Chief Operating Officer, TxCell)  Adrian Bot (Vice President, Scientific Affairs, Kite Pharma)  Vincent Brichard (Vice President, Immuno-Oncology, Celyad)  Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)  Aino Kalervo (Competitive Intelligence Manager, Strategy & Business Development, Theravectys)  Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital)  Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado) The research includes brief profiles, featuring an overview of the company, its financial information (if available), and a description of its product(s), highlighting type of therapy and current development status. Each company profile includes technology portfolio (if available), recent developments related to T-cell immunotherapies and manufacturing capabilities of the companies.  Autolus  bluebird bio  CARsgen Therapeutics  Celgene (A Bristol Myers Squibb Company)  Cellectis  Cellular Biomedicine Group  Innovative Cellular Therapeutics  Iovance Biotherapeutics  Kite Pharma (A Gilead Sciences Company)  Kuur Therapeutics  Noile-Immune Biotech  Novartis  Shanghai Genechem  Sinobioway Cell Therapy  Takara Bio  Ziopharm Oncology For additional details, please visit https://www.rootsanalysis.com/reports/view_document/car-t-therapies-market/269.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Global T-Cell Therapies Market (5th Edition), 2021 – 2030 2. mRNA Therapeutics and Vaccines Market, 2020-2030 3. Gene Therapies Market (4th Edition): Industry Trends and Global Forecasts, 2020-2030 4. Oncolytic Virus Therapy Market: Pipeline Review, Developer Landscape and Competitive Insights, 2020-2030 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
    CAR-T Therapies Market (3rd Edition) | Industry Analysis | Market Size | 2030
    CAR-T Therapies market report features an extensive study of the current market landscape and future potential of the industry players
    WWW.ROOTSANALYSIS.COM
    0 Comments 0 Shares

No results to show

No results to show

No results to show

No results to show

Sponsored